Press Release

CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Lisa Amaya Price as Senior Vice President, Human Resources.  Ms. Amaya Price brings more than 20 years of experience with a strong track record of developing human resource strategies and leading talent recruitment, selection and development in the biopharmaceutical industry. 

Scholar Rock Senior Vice President, Human Resources Lisa Amaya Price

“I am delighted to welcome Lisa to Scholar Rock to lead our efforts to attract and invest in the best talent, optimize our organizational design, and continue to evolve our culture of innovation,” said Nagesh Mahanthappa, Ph.D., President and CEO of Scholar Rock.  “Lisa’s breadth and depth of experience will be invaluable as we continue to build a team that is committed to advancing our growing portfolio of product candidates that aims to improve the lives of patients.”

“I am thrilled to join Scholar Rock during this dynamic phase of the company’s evolution; investments in our people and organization are key to our formula for success as we advance multiple product candidates toward addressing unmet patient needs in neuromuscular disorders, cancer, fibrosis, and anemia,” said Ms. Amaya Price.  “I look forward to working with the Scholar Rock team to develop a progressive and aligned human resource strategy in a work environment where talent and culture continue to be a driver of innovation with meaningful patient impact.”

Ms. Amaya Price joins Scholar Rock from Takeda Pharmaceuticals Company Ltd., where she led the organizational design and talent selection related to the company’s acquisition of Shire Pharmaceuticals.  Previously, she was Global Head of Human Resources for Takeda’s vaccine business unit and led the strategic redesign of multiple functions to enable the unit to grow from R&D to commercialization on a global scale.  Before joining Takeda, Ms. Amaya Price served in various positions of increasing responsibility at Biogen, Inc. from 2008 to 2016, including most recently Senior Director, Human Resources of R&D.  Earlier in her career, she held human resource leadership positions at Interpublic Group, Inc., Metro International S.A., and American Financial Systems, Inc.  Ms. Amaya Price received a BA from Bard College, an MA from Simmons College, and an MBA from F.W. Olin Graduate School of Business at Babson College.       

About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.  Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.  Scholar Rock’s newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level.  By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect.  Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of new executives to influence Scholar Rock’s progress, Scholar Rock’s ability to develop its pipeline, and Scholar Rock’s growth expectations. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Annual Report on Form 10-K for the quarter and year ended December 31, 2018, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7dd8455f-9d44-4631-93b1-d2a13eeca124

Scholar Rock Contact:
Investors/Media
Catherine Hu
chu@scholarrock.com
917-601-1649

Media Contact:
The Yates Network
Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412